IMMUNOSABR is a strong consortium between 17 partners from 8 European Union member states. IMMUNOSABR is a strong multi-disciplinary collaboration between Europe’s leading institutions on radiotherapy and medical oncology. The majority of the partners have worked together before in both preclinical and clinical studies. All partners have a valid role in the project and the complementary expertise of each partner is required to reach the objectives proposed (see below). The consortium has a strong involvement of 3 SMEs (PG, HIV, ptTh) that will ensure the commercialisation of L19-IL2 (PG) and the development of biomarkers for a clinical decision support system (HIV, ptTh).